Julie Alimi - Medincell Head Legal
| MEDCL Stock | EUR 17.42 0.26 1.52% |
Insider
Julie Alimi is Head Legal of Medincell SA
| Phone | 33 4 67 02 13 67 |
| Web | https://www.medincell.com |
Medincell Management Efficiency
The company has return on total asset (ROA) of (0.3954) % which means that it has lost $0.3954 on every $100 spent on assets. This is way below average. Medincell's management efficiency ratios could be used to measure how well Medincell manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Serge Picaud | Gensight Biologics SA | N/A | |
| FFPM MBA | Biophytis SA | 52 | |
| Benoit Canolle | Biophytis SA | 45 | |
| Pierre MBA | Abivax SA | N/A | |
| Scott Jeffers | Gensight Biologics SA | N/A | |
| Dominique MD | OSE Pharma SA | 68 | |
| Prof Cepko | Gensight Biologics SA | N/A | |
| Philippe Rousseau | Biophytis SA | 52 | |
| JeanPascal PharmD | OSE Pharma SA | N/A | |
| Regina Jehle | Abivax SA | N/A | |
| Clothilde Caillet | Gensight Biologics SA | N/A | |
| Anne Pascard | Abivax SA | N/A | |
| Alain MD | OSE Pharma SA | N/A | |
| Pr Roska | Gensight Biologics SA | N/A | |
| Philippe MD | Abivax SA | 65 | |
| Paul Gineste | Abivax SA | N/A | |
| Raquel Lizarraga | Abivax SA | N/A | |
| Silvia MD | OSE Pharma SA | N/A | |
| Teylan | Biophytis SA | N/A | |
| Prof Ehrlich | Abivax SA | N/A | |
| JoseAlain MD | Gensight Biologics SA | N/A | |
Management Performance
| Return On Asset | -0.4 |
Medincell SA Leadership Team
Elected by the shareholders, the Medincell's board of directors comprises two types of representatives: Medincell inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Medincell. The board's role is to monitor Medincell's management team and ensure that shareholders' interests are well served. Medincell's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Medincell's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Joel Richard, Member Board | ||
| Quiterie Beauregard, Head Portfolio | ||
| Helen Martin, Head Management | ||
| Julie Alimi, Head Legal | ||
| Sebastien Enault, Chief Officer | ||
| Christophe Douat, Chairman of the Management Board | ||
| Jaime Arango, Financial and Administrative Director | ||
| David Heuze, Head Board | ||
| Adolfo Noriega, Head Board | ||
| Franck Pouzache, Chief Officer |
Medincell Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Medincell a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -0.4 | |||
| Operating Margin | (3.25) % | |||
| Current Valuation | 180.29 M | |||
| Shares Outstanding | 25.22 M | |||
| Shares Owned By Insiders | 47.40 % | |||
| Shares Owned By Institutions | 18.95 % | |||
| Price To Book | 27.59 X | |||
| Price To Sales | 20.97 X | |||
| Revenue | 4.09 M | |||
| Gross Profit | 4.09 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Medincell Stock Analysis
When running Medincell's price analysis, check to measure Medincell's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Medincell is operating at the current time. Most of Medincell's value examination focuses on studying past and present price action to predict the probability of Medincell's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Medincell's price. Additionally, you may evaluate how the addition of Medincell to your portfolios can decrease your overall portfolio volatility.